Significance of melatonin in the diagnostics of ceratin internal diseases and the perspectives of using melatonin in practical medicine /

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review is devoted to the analysis of the role of melatonin in the clinic of internal diseases. There are many data testified that melatonin level and its circadian changes may be considered as the markers of the risk of the development of several diseases and pathologies during the arrangement of the program of prophylaxis. The biological effects of melatonin in the mechanisms of therapeutic pathology are considered. It has been shown that the regulation of biological rhythms is the most well-known biological function of melatonin. The role of melatonin as pharmacological substance for the treatment and rehabilitation of the patients with internal pathology is discussed.

About the authors

K. I. Proschayev

St Petersburg Insitute of Bioregulation and Gerontology NWB RAMS; Medical-Sanitary Department of the Open Joint-Stock Company «Polymir»; Polotsk Central City Hospital

Author for correspondence.
Email: medaj@eco-vector.com
Russian Federation, St. Peterburg; Novopolotsk (Belarussia); Polotsk (Belarussia)

A. N. Unitskiy

St Petersburg Insitute of Bioregulation and Gerontology NWB RAMS; Medical-Sanitary Department of the Open Joint-Stock Company «Polymir»; Polotsk Central City Hospital

Email: medaj@eco-vector.com
Russian Federation, St. Peterburg; Novopolotsk (Belarussia); Polotsk (Belarussia)

T. V. Kvetnaya

St Petersburg Insitute of Bioregulation and Gerontology NWB RAMS; Medical-Sanitary Department of the Open Joint-Stock Company «Polymir»; Polotsk Central City Hospital

Email: medaj@eco-vector.com
Russian Federation, St. Peterburg; Novopolotsk (Belarussia); Polotsk (Belarussia)

I. V. Knyazkin

St Petersburg Insitute of Bioregulation and Gerontology NWB RAMS; Medical-Sanitary Department of the Open Joint-Stock Company «Polymir»; Polotsk Central City Hospital

Email: medaj@eco-vector.com
Russian Federation, St. Peterburg; Novopolotsk (Belarussia); Polotsk (Belarussia)

E. S. Golubitskaya

St Petersburg Insitute of Bioregulation and Gerontology NWB RAMS; Medical-Sanitary Department of the Open Joint-Stock Company «Polymir»; Polotsk Central City Hospital

Email: medaj@eco-vector.com
Russian Federation, St. Peterburg; Novopolotsk (Belarussia); Polotsk (Belarussia)

A. V. Antropov

St Petersburg Insitute of Bioregulation and Gerontology NWB RAMS; Medical-Sanitary Department of the Open Joint-Stock Company «Polymir»; Polotsk Central City Hospital

Email: medaj@eco-vector.com
Russian Federation, St. Peterburg; Novopolotsk (Belarussia); Polotsk (Belarussia)

O. E. Antropova

St Petersburg Insitute of Bioregulation and Gerontology NWB RAMS; Medical-Sanitary Department of the Open Joint-Stock Company «Polymir»; Polotsk Central City Hospital

Email: medaj@eco-vector.com
Russian Federation, St. Peterburg; Novopolotsk (Belarussia); Polotsk (Belarussia)

References

  1. Анисимов В. Н., Арутюнян А. В., Хавинсон В. X. Антиоксидантная роль эпиталамина и мелатонина // Геронтологические аспекты пептидной регуляции функций организма. СПб.: Наука, 1996. С. 15.
  2. Анисимов В. H., Кветной И М., Комаров Ф. И. и др. Мелатонин в физиологии и патологии желудочно-кишечного тракта. М.: Советский спорт, 2000. 184 с.
  3. Анисимов В. Н., Рейтер Р. Функция эпифиза при раке и старении // Вопросы онкологии. 1990. Т. 36. № 3. С. 259-268.
  4. Анисимов В. Н., Хавинсон В. X., Морозов В. Г. Эпифиз и рак // Успехи совр. биол. 1980. Т. 89. № 2. С. 283-291.
  5. Берштейн Л. М. Эволюционная онкоэндокринология // Журн. эвол. биохим. и физиол. 2001. Т. 3 7. № 5. С. 446-449.
  6. Бондаренко Л. А. Современные представления о физиологии эпифиза // Нейрофизиол. 1997. Т. 29. № 3. С. 212-237.
  7. Вознесенская Л. А., Продукция мелатонина у больных язвенной болезнью двенадцатиперстной кишки: Автореф. дис. ... канд. мед. наук. М., 1998.
  8. Дильман В. М. Эндокринологическая онкология. Л.: Медицина, 1983. 409 с.
  9. Ивашкин В. Т., Лапина Т. Л. Лечение язвенной болезни: новый век — новые достижения — новые вопросы // Рус. мед. журн. 2002. № 4. С. 1-4.
  10. Кветная Т. В., Князькин И. В. Мелатонин: Роль и значение в возрастной патологии. СПб.: Изд-во ВмедА, 2004. 111 с.
  11. Кветная Т. В., Князькин И. В., Кветной И. М. Мелатонин — нейроэндокринный маркер возрастной патологии. СПб.: ДЕ АН, 2005. 144 с.
  12. Кветной И. М., Левин И. М. Мелатонин и опухолевый рост // Экспер. онкол. 1986. № 4. С. 11-15.
  13. Малиновская И. К., Комаров Ф. И., Рапопорт С. И. и др. Мелатонин в лечении язвенной болезни двенадцатиперстной кишки // Клин. мед. 2006. № 1. С. 5—11.
  14. Минушкин О. Н. Язвенная болезнь. М., 1995. 152 с.
  15. Осадчук М. A., Киричук В. Ф., Кветной И. М. Диффузная нейроэндокринная система: общебиологические и гастроэнтерологические аспекты. Саратов: Изд-во СГМУ, 1996. 128 с.
  16. Репетий Н. Г. К вопросу о значении мелатонина в этиопатогенезе артериальной гипертонии у лиц пожилого возраста // Успехи геронтологии. 2005. Т. 16. С. 105—109.
  17. Смирнова И. О., Кветной И. М., Князькин И. В., Данилов С. И. Нейроиммуноэндокринология кожи и молекулярные маркеры ее старения. СПб.: ДЕАН, 2005. 288 с.
  18. Фаттахова Ф. А., Мальцева Л. И., Гарипова Г. Р. Экскреция мелатонина у больных с гиперпластическими процессами эндометрия в климактерии // Климактерий. 2001. № 3. С. 46-51.
  19. Хейфец В. X., Кветной И. М., Князькин И. В. и др. Роль нейроиммуноэндокринных механизмов в онкогеронтологии предстательной железы и мочевого пузыря. СПб.: Система, 2004. 92 с.
  20. Agrasal С., Esquifino A. L, Garcia-Bonacho М. et al. Effect of melatonin on 24h changes in plasma protein levels during the preclinical phase of Friend’s adjuvant arthritis in rats, Reyes // Chronobiol. Int. 2001. Vol. 18. № 3. P. 435-446.
  21. Anisimov К. N. The role of pineal gland in the breast cancer development // Crit. Rev. Oncol. Hematol. 2003. Vol. 46. № 3. P. 221-234.
  22. Aoki M., Yokota Y., Hayashi T. et al. Disorder of the saliva melatonin circadian rhythm in patients with Meniere’s disease // Acta Neurol. Scand. 2006. Vol. 113. № 4. P. 256-261.
  23. Arendt J. Melatonin: characteristics, concerns, and prospects // J. Biol. Rhythms. 2005. Vol. 20. № 4. P. 291-303.
  24. Axelrod J., Weissbach H. Enzymatic O-methylation of N-acetyl-serotonin to melatonin // Science. 1960. Vol. 131. P. 1312-1318.
  25. Bandyopadhyay D., Biswas K., Bandyopadhyay U. et al. Melatonin protects against stress-induced gastric lesions by scavenging the hydroxyl radical // J. Pineal Res. 2000. Vol. 29. P. 248-252.
  26. Bartsch C., Bartsch H. Significance of melatonin in malignant diseases // Wien Klin. Wochenschr. 1997. Vol. 109. P. 722-729.
  27. Bartsch C., Bartsch H., Karasek M. Melatonin in clinical oncology // Neuroendocrinol. Lett. 2002. Vol. 236. Suppl. 1. P. 30-38.
  28. Benitez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease // J. Pineal Res. 2006. Vol. 40. № 1. P. 1-9.
  29. Besedovsky H. O., Del Rey A. Immune-neuroendocrine interactions: facts and hypotheses // Endocr. Rev. 1996. Vol. 17. P. 64-102.
  30. Blask D. E. Melatonin biosynthesis, physiological effects, and clinical applications // Melatonin in oncology / Yu H. S., Reiter R. J., eds. Boca Raton: CRC Press, 1993. P. 447-475.
  31. Blask D. E., Hill S. M. Melatonin and cancer: basis and clinical aspects // Melatonin: Clinical Perspectives / A. Miles, D. R. S. Philbrick, eds. Oxford: Oxford Univ. Press, 1988. P. 128-173.
  32. Blask D. E., Wilson S. T., Lemus-Wilson A. M. The oncostatic and oncomodulatory role of the pineal gland and melatonin // Advances in pineal research: Vol. 7 / G. J. V. Maestroni, A. Conti, R. J. Reiter, eds, London: John Libbey and Comp., 1994. P. 235-241.
  33. Brzezinski A. Melatonin in humans // N. Engl. J. Med. 1997. Vol. 16. P 95-186.
  34. Budenik G. A. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin // Biol. Signals Recept. 2001. Vol. 10. P. 350-366.
  35. Burch J. B., Yost M. G., Johnson W., Allen E. Melatonin, sleep, and shift work adaptation // J. Occup. Environ. Med. 2005. Vol. 47. № 9. P. 893-901.
  36. Callaghan B. D. Does the pineal gland have a role in the psychological mechanisms involved in the progression of cancer? // Med. Hypotheses. 2002. Vol. 59. № 3.P. 302-311.
  37. Cardinali D. P., Esquifino A. L, Garcia A. P, Cano P. Melatonin role in experimental arthritis // Curr. Drug Targets Immune Endocr. Metabol. Disord. 2004. Vol. 4. № 1. R 1-10.
  38. Cardinali D. Pю, Esquifino A. I. Circadian disorganization in experimental arthritis // Neurosignals. 2003. Vol. 12. № 6. P. 267-282.
  39. Cardinali D. P., Furio A. M., Reyes M. P. Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent // Ann. N. Y. Acad. Sci. 2005. Vol. 1057. P. 327-336.
  40. Castrillon P. O., Esquifino A. I., Varas A. Effect of melatonin theatment on 24-h variations in responses to mitogens and lymphocyte subset populations in rat submaxillary lymph nodes // J. Neuroendocrinol. 2000. Vol. 12. № 8. P. 758-765.
  41. Chen Q., Wei W. Effects and mechanisms of melatonin on inflammatory and immune responses of adjuvant arthritis rat // Int. Immunopharmacol. 2002. Vol. 2. № 10. P. 1443-1449.
  42. Chik C. L., Ho A. K. Pituitary adenylate cyclase-activating polypeptide: control of rat pineal cyclic AMP and melatonin but not cyclic GMP // J. Neurochem. 1995. Vol. 64. R 2111-2117.
  43. Cohen M., Small R. A., Brzezinski A. Hypotheses: melatonin/steroid combination contraceptives will prevent breast cancer // Breast Cancer Res. Treat. 1995. Vol. 33. № 3. R 257-264.
  44. Cutolo M., Masi A. T. Circadian rhythms and arthritis // Rheum. Dis. Clin. North. Am. 2005. Vol. 31. № 1. R 115-129.
  45. Cutolo M., Maestroni G. J., Otsa K. et al. Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winer time: a north and south Europe comparison // Ann. Rheum. Dis. 2005. Vol. 64. № 2. P. 212-216.
  46. Cutolo M., Villaggio B., Otsa K. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease’s symptoms // Autoimmun. Rev. 2005. Vol. 4. № 8. R 497-502.
  47. Dose-response relationship between light irradiance and the suppression of plasma melatonin in human volunteers / Brainard G. C., Lewy A. J., Menaker M. et al. // Brain Res. 1988. Vol. 454. R 212-218.
  48. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlledstudy / G. Bellipanni, R Bianchi, W. Pierpaoli et al. // Exp. Gerontol. 2001. Vol. 36. № 2. R 297-310.
  49. Elevated blood pressure after pinealectomy in the rat / Vaughan G. M., Becker R., Allen J., Vaughan M. //J. Endocrinol. Invest. 1979. Vol. 2. R 281-286.
  50. Esrefoglu M., Gul M., Ates B., Selimoglu M. A. Ultrastructural clues for the protective effect of melatonin against oxidative damage in cerulean- induced pancreatitis // J. Pineal Res. 2006. Vol. 40. № 1. P 92-97.
  51. Esrefoglu M., Gul M., Ates B. et al. Antioxidative effect of melatonin, ascorbic acid and N-acetilcysteine on caerulein-induced pancreatitis and associated liver injury in rats // World J. Gastroenterol. 2006. Vol. 12. № 2. R 259-264.
  52. Garcia-Caballero T., Gallego R., Roson E. et al. Localization of serotonin-like immunoreactivity in the Merkel cells of pig snout skin // Anat. Rec. 1999. Vol. 225. R 267-271.
  53. Grin W, Grunberger W. Significant correlation between melatonin deficiency and endometrial cancer // Gynecol. Obstet. Invest. 1998. Vol. 45. № 1.R62-65A.
  54. Is the pineal gland involved in the pathogenesis of endometrial carcinoma / R. Sandyk, P. G. Anastasiadis, P. A. Anninos, N. Tsagas // Int. J. Neurosci. 1992. Vol. 62. № 1-2. R 89-96.
  55. Ha E., Choe В. K., Jung К. H. et al. Positive relationship between melatonin receptor type IB polymorphism and rheumatoid factor in rheumatoid arthritis patients in the Korean population // J. Pineal Res. 2005. Vol. 3 9. № 2. R 201-205.
  56. Hamon M. Serotonin: 5-hydroxytryptamine (5- HT) //Neuropeptides and neuromediateurs. 1992. Vol. 23. R 287-292.
  57. Hansson I., Holmdahl R., Mattsson R. Pinealectomy ameliorates collagen IL induced arthritis in mice // Clin. Exp. Immunol. 1993. Vol. 92. № 3. R 432-436.
  58. Jansen K. L. R., Dragunow M., Faull R. L. M. Sigma receptors are highly concentrated in the rat pineal gland // Brain Res. 1990. Vol. 507. P. 158-160.
  59. Jimenez-Caliani A. J., Jimenez-Jorge S., Molinero P. et al. Dual effect of melatonin as proin-flammatory and antioxidant in collagen-induced arthritis in rats // J. Pineal Res. 2005. Vol. 38. № 2. R 93-99.
  60. Karasek М., Szuflet A., Chrzanowski W. Decreased melatonin nocturnal concentrations in hemodialyzed patients // Neuroendocrinol. Lett. 2005. Vol. 26. № 6. P. 653-656.
  61. Karsliogly L, Ertekin M. V., Taysi S. Radioprotective effects of melatonin on radiation-induced cataract // J. Radiat. Res. 2005. Vol. 46. № 2. P. 277-282.
  62. Kato K., Murai L, Asai S. et al. Circadian rhythm of melatonin and prostaglandin in modulation of stress-induced gastric mucosal lesions in rats // Aliment. Pharmacol. Then 2002. Vol. 16 (Suppl. 2). P. 29-34.
  63. Krause D. N., Dubocovich M. L. Melatonin re ceptors // Annu. Rev. Pharmacol. Toxicol. 1991. Vol. 31. P. 549-568.
  64. Larson J., Jessen R. E., Uz T. Impaired hip pocampal long-term potentiation in melatonin MT2 receptor-deficient mice // Neurosci. Lett. 2006. Vol. 393. № 1. P. 23-26.
  65. Lem er A., Case J., Takahashi J. Isolation of melatonin, the pineal gland factor that lightens melanocytes // J. Am. Chern. Soc. 1958. Vol. 81. P. 6084-6086.
  66. Maestroni G. J. The immunotherapeutic potential of melatonin // Expert Opin. Investig. Drugs. 2001. Vol. 10. № 3. P. 467-476.
  67. Maestroni G. J., Cardinali D. R, Esquifino A. L, Pandi-Perumal S. R. Does melatonin play a disease-promoting role in rheumatoid arthritis? // J. Neuroimmunol. 2005. Vol. 158. № 1—2. P. 106-111.
  68. Marquez E., Sanchez-Fidalgo S., Calvo J. R. etal. Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis // J. Pineal Res. 2006. Vol. 40. № 1. P. 48-55.
  69. Nicole-Smith L. Casuality, menopause, and depression: a critical review of the literature // BMJ. 1996. № 11. P. 229-232.
  70. Pandi-Perumal S. R., Zisapel N., Srinivasan E., Cardinali D. R Melatonin and sleep in aging population // Exp. Gerontol. 2005. Vol. 40. № 12. P. 911-925.
  71. Pawlikowski M., Winczyk K., Karasek M. Oncostatic action of melatonin: facts and question marks // Neuroendocrinol. Lett. 2002. Vol. 23 (Suppl. 1). P. 24-29.
  72. Poeggeler B., Reiter R. J., Tan D.-X., ChenL.-D., Manchester L. C. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: A hypothe s is //! Pineal Res. 1993. Vol. 14. P. 151—168.
  73. Ponsonby A. L., Lucas R. M., van der Mei I. A. UVR, vitamin D and three autoimmune diseases-multiple sclerosis, type 1 diabetes, rheumatoid arthritis // Photochem. Photobiol. 2005. Vol. 81. № 6. P. 1267-1275.
  74. Rahman M. A., Azuma Y., Fukunaga H. et al. Serotonin and melatonin, neurohormones for homeostasis, as novel inhibitors of infections by the intracellular parasite Chlamydia // J. Antimicrob. Chemother. 2005. Vol. 56. № 5. P. 861-868.
  75. Rakonczay Z. Jr., Lonovics J., Takacs T. Effectiveness of a treatment based on melatonin in five patients with systemic sclerosis // Am. J. Ther. 2006. Vol. 13. № l.P. 84-87.
  76. Regelson W., Pierpaoli W. Melatonin: a rediscovered antitumor hormone // Cancer Invest. 1987. Vol. 5. P. 276-283.
  77. Reiter R. J. Melatonin: clinical relevance // Best Pract. Res. Clin. Endocrinol. Metab. 2003. Vol. 17. № 2. P. 273-285.
  78. Roman O., Seres J., Herichova I. et al. Daily profiles of plasma prolactin (PRL), growth hormone (GH), insulin-like growth factor-1 (IGF-1), luteinizing hormone (LH), testosterone, and melatonin, and of pituitary PRL mRNA and GH mRNA in male Long Evans rats in acute phase of adjuvant arthritis // Chronobiol. Int. 2003. Vol. 20. № 5. P. 823-836.
  79. Sousa S. C., Castilho R. E. Protective effect of melatonin on rotenone plus Ca2+- induced mitochondrial oxidative stress and PC 12 cell death // Antioxid. Redox. Signal. 2005. Vol. 7. № 9-10. P. 1110-1116.
  80. Sulli A., Maestroni G. J., Villaggio B. et al. Melatonin serum levels in rheumatoid arthritis // Ann. N. Y. Acad. Sci. 2002. № 966. P. 276-283.
  81. Szabolcs A., Reiter R. J., Letoha T. et al. Effect of melatonin on the severity of L-arginine-induced experimental acute pancreatitis in rats // World J. Gastroenterol. 2006. Vol. 12. P. 251-258.
  82. Wang Y. T., Chen S. L., Xu S. Y. [Effect of melatonin on the expression of nuclear factor-kappa В and airway inflammation in asthmatic rats] // Zhonghua Er Ke Za Zhi. 2004. Vol. 42. № 2. P. 94-97.
  83. Weekley B. L. Melatonin-induced relaxation of rat aorta: interaction with adrenergic agonists // J. Pineal Res. 1991. Vol. 11. P. 28-34.
  84. Yen S. S. C., Jaffe R. B. Reproductive endocrinology. Philadelphia: W. B. Saunders Com., 1998. P. 39-40.
  85. Yildirim Z., Kotuk M., Erdogan H. et al. Preventive effect of melatonin on bleomycin-induced lung fibrosis in rats //J. Pineal Res. 2006. Vol. 40. № l.P. 27-33.
  86. http://medicpress.ru/archive/707155.html
  87. http://ritmbio.narod.ru/Melat.htm
  88. http://www.catboy.com/mlm-spb/testing/msk_articles.htm#03
  89. http://www.medlit.ru/medrus/ta/ta050232.htm

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2007 Proschayev К. I., Unitskiy A. N., Kvetnaya Т. V., Knyazkin I. V, Golubitskaya Е. S., Antropov А. V. Antropova О. Е.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.